Compare Abeona Therapeutics Inc (ABEO) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Coinbase Global, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Coinbase Global, Inc. trades at $160.05 (market cap $43.08B). The key difference: Coinbase Global, Inc. is far larger — about 115.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | COIN | |
|---|---|---|
Market Cap | $373.32M | $43.08B |
Sector | Health | Technology |
52-Week High | $7.23 | $419.78 |
52-Week Low | $4.17 | $141.09 |
Enterprise Value | $228.22M | $40.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
COIN trades at $163.51, down 1.19% over 24 hours, with a bearish technical signal and mixed earnings history. The company reported $7.18B revenue in 2025 with a net income margin of 12.2%, though recent quarters showed misses against EPS expectations. Analyst consensus remains bullish with a $233.08 price target, but cash flow trends indicate potential pressure as operating cash flow declined to $2.4B in 2025 from $2.6B in 2024.
The outlook for COIN hinges on execution amid volatile crypto markets, with 55% of analysts rating it a buy. Key risks include regulatory uncertainty and competitive threats, while institutional adoption growth offers upside. Investors should weigh high valuation multiples against earnings volatility and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
